ACIU

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today Amended Morphomer® Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer® small molecules Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 Cash resources of CHF 74.8 million as of March 31, 2026, provide funding into Q4 2027 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today provided financial and corporate updates for the quarter ended March 31, 2026. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation inhibitor small molecules, respectively. These have the potential to change the way we target the proteinopathies that drive Alzheimer’s and other neurodegenerative diseases (NDDs). This is further exemplified by the presentation of the interim results for ACI-7104 at AD/PD 2026 showing that our active immunotherapy targeting a-synuclein (a-syn) has the potential to modify disease pathology in Parkinson’s disease (PD). We also advanced our NLRP3 inhibitor ACI-19764 into clinical development, further demonstrating the power of AC Immune’s technology to target the key pathways that contribute to neurodegeneration. “We are now moving towards multiple value inflection points during 2026. These include Phase 2 data readouts on our active immunotherapies ACI-7104 and ACI-24, and initial results from the Phase 1 trial of ACI-19764 also anticipated this year.” Q1 2026 and Subsequent Highlights: ACI-24 anti-Abeta active immunotherapy As announced separately today, AC Immune has initiated the final cohort, AD4, in the ongoing Phase 1b/2 ABATE trial of ACI-24 to treat Alzheimer's Disease Treatment of the first patient...

LAUSANNE, Switzerland (AP) — LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Thursday reported a loss of $18.9 million in its first quarter. On a per-share basis, the Lausanne, Switzerland-based company said it had a loss of 19 cents. The biopharmaceutical company posted revenue of $1.4 million in the period. The company's shares closed at $2.93. A year ago, they were trading at $1.70. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACIU at https://www.zacks.com/ap/ACIU

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson’s disease NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer’s disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Q3 2026 Cash resources of CHF 91.4 million as of December 31, 2025, provide funding to the end of Q3 2027 before any potential milestone payments Lausanne, Switzerland, March 13, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting α-synuclein. Evidence that ACI-7104 appears to slow the rate of progression in early Parkinson’s disease (PD) further demonstrates the potential for active immunotherapies as disease-modifying treatments with the potential to slow or prevent neuronal damage.” “Our novel Morphomer® small-molecule therapeutics complement these programs by targeting intracellular mechanisms, enabling intervention at the earliest stages of disease. ACI-19764, a brain-penetrant NLRP3 inhibitor with potential to treat numerous diseases both within and beyond neurodegeneration, is now in a Phase 1 trial.” Full Year 2025 and Subsequent Highlights: ACI-7104 anti-α-synuclein active immunotherapy Reported positive interim safety and efficacy results from Part 1 of the Phase 2 VacSYn trial of our wholly-owned anti-α-synuclein active immunotherapy ACI-7104 in early PD. Results suggest, for the first time, that targeting underlying α-synuclein pathology with an active immunotherapy may slow the rate of progression of Parkinson’s disease. These results could translate into a shift from treating symptoms toward true disease modification in PD Clear safety profile with no cli...

LAUSANNE, Switzerland (AP) — LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Friday reported a loss of $18 million in its fourth quarter. The Lausanne, Switzerland-based company said it had a loss of 18 cents per share. The biopharmaceutical company posted revenue of $423,000 in the period. For the year, the company reported that its loss widened to $85 million, or 84 cents per share. Revenue was reported as $4.3 million. The company's shares closed at $3. A year ago, they were trading at $2.32. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACIU at https://www.zacks.com/ap/ACIU

AC Immune (ACIU) remains unprofitable, but has managed to shrink its losses by an average of 5.9% per year over the last five years. With consensus forecasts calling for annual earnings growth of 66.51% and a transition to profitability expected within three years, the numbers position the company as a high-growth biotech. Revenue is projected to climb 55.6% annually. The current Price-to-Book Ratio of 4.2x stands out above peers and the US Biotech industry average. Investors are likely to weigh the company’s rapid growth path and discount share price against its near-term volatility and relatively high valuation. See our full analysis for AC Immune. The real test is how these earnings figures compare to the market’s big stories about AC Immune. Next, we’ll see where the community narratives get confirmed, and where the numbers may force a rethink. Curious how numbers become stories that shape markets? Explore Community Narratives AC Immune has reduced its annual losses by 5.9% on average over the last five years, a trend that stands out in the biotech space where sustained deficits are often the norm. Surprising many, the rate of narrowing losses not only suggests the company’s cost controls are working, but also this contrasts with the prevailing market view that emerging biotechs typically accumulate larger losses before profitability. This trend may indicate a potentially smoother path toward positive earnings. it suggests that the expected transition to profitability in the next three years is more than just hype, especially relative to sector averages. Projected revenue growth of 55.6% per year sharply exceeds the broader US market forecast of 10.5% annually. This highlights AC Immune's trajectory as one of the more aggressive growth profiles among peers. What’s notable is that, despite this rapid pace, the prevailing market view points out such speed puts the spotlight on execution risks, since market sentiment for high-growth biotechs often hinges on hit-or-miss clinical milestones rather than steady performance. the company’s ability to capture upside will depend on converting this revenue surge into tangible milestones that can ease concerns about volatility. Shares trade at $3.30 versus a DCF fair value estimate of $66.83, leaving a notable discount even as the Price-to-Book Ratio sits at 4.2x and remains well above biotech industry norms. The pre...

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn Cash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestones Peer-reviewed papers covering groundbreaking results including clinical data on ACI-35.030 (JNJ-64042056) published in eBioMedicine and preclinical data on first-in-class PET tracers for imaging TDP-43 pathology published in Nature Communications IND/CTA filing for small molecule NLRP3 inhibitor ACI-19764 and the start of IND-enabling studies for Morphomer-Tau aggregation inhibitor both expected by year-end Lausanne, Switzerland, November 4, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended September 30, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We have sharpened our investment focus on our most valuable assets following a strategic review. Our pipeline assets have the potential to transform treatment and enable prevention of neurodegenerative disease. Our active immunotherapies for precision prevention of neurodegenerative diseases continue to make strong progress through Phase 2 development in Alzheimer’s disease and Parkinson’s disease. These are complemented by novel small-molecule therapeutics targeting intracellular mechanisms of neurodegenerative diseases. Importantly, our recent pipeline prioritization has extended our cash runway to the end of Q3 2027, without including anticipated milestone payments from our existing collaborations or potential payments from new business development deals. “We are now moving towards multiple value-inflection points. Further interim results from Part 1 of the VacSYn trial of ACI-7104.056, our wholly owned anti-alpha-synuclein active immunotherapy for Parkinson’s disease, are expected this quarter. Our two partnered active immunotherapy programs are continuing to progress according to plan. We also published data in The Lancet’s eBioMedicine on ACI-35.030 (JNJ-64042056) with the first clinical demonstration that our SupraAntigen® platform ge...

LAUSANNE, Switzerland (AP) — LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Tuesday reported a third-quarter loss of $19.8 million, after reporting a profit in the same period a year earlier. The Lausanne, Switzerland-based company said it had a loss of 20 cents per share. The biopharmaceutical company posted revenue of $1.2 million in the period. The company's shares closed at $3.18. A year ago, they were trading at $3. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACIU at https://www.zacks.com/ap/ACIU

AC Immune (ACIU) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This biopharmaceutical company is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -466.7%. Revenues are expected to be $1.52 million, down 94.8% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 4.35% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Ea...

AC Immune (NasdaqGM:ACIU) has stirred investor curiosity following the publication of Phase 1b/2a trial results for its active immunotherapy, ACI-35.030, in partnership with Janssen. The data in eBioMedicine highlights rapid and lasting immune responses without notable safety issues. See our latest analysis for AC Immune. With the encouraging ACI-35.030 trial results making headlines, AC Immune’s share price has shown only modest moves recently, but long-term total shareholder returns tell the broader story. Momentum has been muted, with performance reflecting both ongoing R&D promise and market caution. If breakthroughs in biotech grab your attention, it’s a great moment to explore what other innovators are up to: See the full list for free. Against this backdrop of promising clinical progress, the real question emerges: does the current share price reflect AC Immune’s potential, or might investors find an overlooked opportunity before markets price in possible breakthroughs? AC Immune is trading with a price-to-sales ratio of 9.6x, which is seen as attractive compared to its main competitors and the broader US biotech industry. The price-to-sales ratio compares a company’s stock price to its revenue per share, providing a way to evaluate fast-growing or unprofitable biotech firms where profits are not yet the main story. This figure suggests investors are currently paying less for every dollar of AC Immune’s sales than for the industry (10.5x) or peer average (13.8x). This positions the stock as a relative bargain by headline numbers. However, compared to the fair price-to-sales ratio of 0.9x, the current multiple appears much higher than what a regression-based analysis would suggest as justified. Should valuations revert, there could be a significant adjustment. Explore the SWS fair ratio for AC Immune Result: Price-to-Sales of 9.6x (ABOUT RIGHT) However, slow revenue growth or continued net losses could challenge bullish expectations if AC Immune's clinical breakthroughs do not quickly translate to commercial success. Find out about the key risks to this AC Immune narrative. While headline price-to-sales metrics suggest AC Immune is relatively well-priced among biotech peers, our DCF model presents a very different picture. By estimating the company's future cash flows, the SWS DCF model indicates AC Immune trades significantly below its calculated fair...

The publication is entitled "Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer’s disease: a Phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study" and reports the following key findings from the completed trial (NCT04445831): ACI-35.030 is based on AC Immune’s proprietary SupraAntigen® technology which anchors the pTau peptide in a liposome and also incorporates non-Tau T-cell epitopes and adjuvants. JACI-35.054 covalently linked the immunogen to the carrier protein CRM197 and was mixed with adjuvants. Both active immunotherapies used the same target pTau peptide sequence. ACI-35.030 required only one injection to induce anti-pTau Immunoglobulin G (IgG) antibody titers in all participants and consistently boosted levels with subsequent immunizations. JACI-35.054 raised a more heterogenous anti-pTau IgG antibody response and required multiple administrations to reach consistent titers. All participants across all dose-levels were considered anti-pTau IgG responders at 2 weeks post treatment with ACI-35.030. In the two high-dose cohorts, response rates remained between 94% and 100% until week 74. Most participants generated an anti-ePHF antibody response after the first administration and antibody levels further increased with additional immunizations. Antibody titers against unphosphorylated (normal) Tau declined and were not boosted with subsequent administrations of ACI-35.030, demonstrating specific targeting of the pathological Tau species. In contrast, JACI-35.054 induced antibody titers against normal Tau after the second treatment and these increased with subsequent administrations. An exploratory post-hoc analysis showed that at multiple time points for the two highest doses ACI-35.030, treatment resulted in a significant (p<0.05) change from baseline of plasma pTau and brain-derived Tau plasma levels compared to the pooled placebo group. Based on the results from this trial, ACI-35.030 was selected for further clinical testing and is now being investigated in the ongoing Phase 2b ReTain trial (NCT06544616). It is the first active immunotherapy targeting Tau to be investigated in approximately 500 participants with preclinical AD. Reference Sol O. et al, Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-...

Explore AC Immune's Fair Values from the Community and select yours Revenue: CHF1.31m (up 90% from 2Q 2024). Net loss: CHF21.2m (loss narrowed by 6.9% from 2Q 2024). CHF0.21 loss per share (improved from CHF0.23 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 34%. Earnings per share (EPS) also missed analyst estimates by 20%. Looking ahead, revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 4.3% from a week ago. Before we wrap up, we've discovered 2 warning signs for AC Immune (1 is concerning!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025 Third Alzheimer’s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026 Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline Cash resources of CHF 127.1 million (USD157.6 million) as of June 30, 2025, provide funding into Q1 2027 excluding any potential milestone payments Lausanne, Switzerland, August 5, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended June 30, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune is continuing to progress toward precision prevention of neurodegenerative diseases as we approach multiple value-inflection points through the rest of 2025 and beyond. Our industry symposium during the AD/PD™ conference focused on unlocking active immunotherapy for tailored prevention strategies highlighted the momentum of our three active immunotherapies in Phase 2 development. Interim results on ACI-7104.056, our wholly owned a-syn active immunotherapy, reinforced its best-in-class characteristics, showing strong immunogenicity and a favorable safety profile in early Parkinson’s disease. The two partnered programs, ACI-24.060 and ACI-35.030, are also progressing according to plan. In addition, our Morphomer® small molecule drugs targeting a-syn and tau and Morphomer®-antibody drug conjugates (morADC) were featured in several presentations at AD/PD™ 2025. In our exciting early-stage pipeline, ACI-19764, a novel Morphomer® small molecule inhibitor of NLRP3, has now entered studies to enable an Investigational New Drug (IND) filing. “Our strong cash position provides funding into 2027, excluding potential milestone payments, and enables us to advance our ro...